Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions

Article Page

Abstract

Background: Bilastine, a non-sedating H1-antihistamine, is indicated to treat the symptoms of allergic disorders (e.g. rhinoconjunctivitis and urticaria) in adults and adolescents and, more recently, in children. Following its marketing approval, many questions regarding the ideal use of bilastine in various clinical practice situations have been received by the Medical Information Department (MID) of Faes Farma Spain. This article is an update of a previous review, with a focus on recent clinical information on the use of bilastine in paediatric and other populations.

Methods: Results of recent clinical studies in paediatric and other populations as well as questions received and responses provided by the Faes Farma MID.

Results: The information regarding the use of bilastine in paediatric patients is the most relevant aspect of this updated review. The stepwise approval of the paediatric formulations in various countries started with the European Medicines Agency approval in 2017 in accordance with a 2009 Paediatric Investigation Plan, followed by approval in other countries. The queries that are most commonly received by the Faes Farma MID include the potential for drug interactions involving bilastine and other frequently used drugs, and the use of bilastine in special populations or to treat specific symptoms related to allergic conditions. As the concomitant use of many medications is not permitted during clinical trials, the advice provided regarding the concomitant use of other medications with bilastine considers the pharmacological properties of both the drug in question and bilastine, as well as expert opinion. Likewise, advice regarding the use of bilastine in special populations (e.g. patients with renal impairment, obesity, lactose intolerance, and elderly or pregnant individuals) or to treat specific symptoms (e.g. treatment-resistant urticaria, pruritus or BASCULE syndrome) considers the best evidence from a variety of sources, including clinical studies, real-world experience, guideline recommendations and expert opinion.

Conclusion: This updated review provides current data regarding the best use of bilastine in specific situations and patients and identifies areas in which further knowledge is required. Although decisions regarding the use of bilastine may be aided by expert opinion that relies on knowledge of the underlying science, additional research and evidence are required to answer certain queries regarding the use of bilastine.

Keywords: allergic rhinoconjunctivitis, antihistamines, bilastine, drug information, drug interactions, medical information services, paediatrics, safety, urticaria.

Citation: Leceta A, García A, Sologuren A, Campo C. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions. Drugs Context. 2021;10:2021-5-1. https://doi.org/10.7573/dic.2021-5-1

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors are employees of Faes Farma SA, 48940-Leioa, Bizkaia, Spain. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/07/dic.2021-5-1-COI.pdf

Acknowledgements: The authors thank Katherine Lyseng-Williamson, Content Ed Net, for editorial assistance in the preparation of this manuscript; funding for editorial assistance was provided by Faes Farma SA.

Funding declaration: This research was supported by Faes Farma SA.

Copyright: Copyright © 2021 Leceta A, García A, Sologuren A, Campo C. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Leceta A, García A, Sologuren A, Campo C. https://doi.org/10.7573/dic.2021-5-1. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/bilastine-10-and-20-mg-in-paediatric-and-adult-patients:-an-updated-practical-approach-to-treatment-decisions

Correspondence: Amalia Leceta, Medical Department, Faes Farma SA, 48940-Leioa, Bizkaia, Spain. Email: aleceta@faes.es

Provenance: Submitted; externally peer reviewed.

Submitted: 14 May 2021; Accepted: 2 July 2021; Publication date: 10 August 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF